iCAD Appoints Nathaniel Dalton to its Board of Directors
Nashua,
N.H. – January 13, 2020 – iCAD, Inc. (NASDAQ:ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced Nathaniel Dalton was appointed to its Board of Directors.
Mr.
Dalton is one of the founders of the global asset management firm Affiliated
Managers Group, Inc. (NYSE:AMG), where he remains a Director and Senior
Advisor. Mr. Dalton held a range of executive positions at AMG, including
General Counsel, Chief Operating Officer, President and Chief Executive
Officer. He was also the founding investor of Talari Networks, the pioneering
SD-WAN technology company, serving as a board observer for more than a decade;
and is an investor in, and advisor to, several growth companies operating at
the intersection of technology and healthcare. Mr. Dalton is a Trustee of
Boston University and serves on the Investment Committee for its Endowment. He
also serves on the Advisory Board of the Institute for Sustainable Energy. Mr.
Dalton received a J.D. from Boston University School of Law and a B.A. from the
University of Pennsylvania.
“We
are very pleased to add Nate as a Director of our Company. We have had the
opportunity to get to know each other since he first invested in iCAD over a
year ago, and we are confident he will make significant contributions to the
Company,” said Michael Klein, Chairman and CEO. “Not only does he have decades
of experience in both capital markets and in building a significant public
company, but he also brings a proven entrepreneurial approach and understanding
of technology companies. We look forward to working with Nate as we capitalize
on iCAD’s tremendous growth opportunities in both the cancer detection and therapy
parts of our business to create significant value for patients, their
caregivers and our shareholders.”
“I
am very excited to work with the team at iCAD at this time of tremendous
opportunity for the Company,” said Mr. Dalton. “iCAD and its platforms for
cancer detection and cancer therapy have the potential to significantly improve
outcomes for patients and enhance the effectiveness and cost-efficiency of
healthcare services.”
About
iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a
global medical technology leader providing innovative cancer detection and
therapy solutions. For more information, visit www.icadmed.com.
Forward-Looking
Statements
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, including
statements about the future prospects for the Company’s technology platforms
and products. Such forward-looking statements involve a number of known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights, the
impact of supply and manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates to
any information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on the
Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
Investor Relations:
Jeremy Feffer, LifeSci Advisors, on behalf of iCAD,
Inc.
+1-212-915-2568